Deuterium-labelling is a widely used method in the fields of biomedical, chemical and pharmaceutical industry.
The FDA recently approved the first deuterated API, and nowadays several molecules with deuterated moieties are under clinical testing in order to treat Alzheimer’s, cystic fibrosis, Freidreich’s ataxia, and psoriasis. The kinetic isotope effect enhances pharmacokinetic properties of deuterium-labelled molecules, which might lead to high therapeutic values.
Continuous-flow deuteration has been demonstrated in the H-Cube® before, however the possibility to use it in a green chemical solvent is practically unexplored.
Download